Company Overview and News

2
HIMX / Himax Technologies, Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-10-05 sec.gov - 2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
HIMX

1
Himax Pre-Announces Key Financial Results for Third Quarter 2018 Revenue, Gross Margin and EPS All Outperform Guidance

2018-10-05 globenewswire - 1
TAINAN, Taiwan, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today pre-announced preliminary unaudited key financial results for the three months ended September 30th, 2018. The third quarter results exceeded its revenues, gross margin and EPS guidance issued by the Company on August 9, 2018.
HIMX

2
Are Options Traders Betting on a Big Move in Himax Technologies (HIMX) Stock?

2018-09-12 zacks - 2
Investors in Himax Technologies, Inc. (HIMX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 28, 2018 $4.50 Call had some of the highest implied volatility of all equity options today.
HIMX CY

 
Himax Teams up with MediaTek and Megvii to Offer Industry’s First Active Stereo Camera 3D Sensing Reference Design for Android Smartphone

2018-09-05 globenewswire
TAINAN, Taiwan, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (NASDAQ: HIMX), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced collaboration with MediaTek Inc., an industry leading smartphone AP platform provider, and Megvii, the Chinese developer of the world’s biggest open platform of face recognition known as Face++, to offer the industry’s first Active Stereo Camera (ASC) 3D sensing reference design targeting facial recognition and secure online payment for Android smartphone.
HIMX

21
HIMX / Himax Technologies, Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-08-29 sec.gov - 21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer
HIMX

 
Himax Technologies, Inc. to Attend Lake Street 2018 Best Ideas Growth (BIG) Conference on September 13th, 2018

2018-08-23 globenewswire
TAINAN, Taiwan, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced that the Company will attend Lake Street 2018 Best Ideas Growth (BIG) Conference on September 13th, 2018 at the Parker New York Hotel.
HIMX

 
Himax Technologies, Inc. to Attend Credit Suisse 19th Annual Asian Technology Conference on September 6th – 7th, 2018

2018-08-22 globenewswire
TAINAN, Taiwan, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced that the Company will attend Credit Suisse 19th Annual Asian Technology Conference on September 6th – 7th, 2018 at the Grand Hyatt Hotel in Taipei, Taiwan.
HIMX

 
Himax Technologies, Inc. to Attend Morgan Stanley Asia Pacific Corporate Day on September 3rd – 5th, 2018

2018-08-20 globenewswire
TAINAN, Taiwan, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced that the Company will attend Morgan Stanley Asia Pacific Corporate Day on September 3rd – 5th, 2018 at Morgan Stanley Office in Canary Wharf, London.
HIMX MS

153
Stocks To Watch: Alibaba, Target And Energy Plays To Center Stage

2018-08-18 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
FOCS PDD LGCYP LGCYO QEP TJX EL AVGO ABBV FTNT KLXI CORR ESES SDPI TENB LNR RRS WPX FSBW ESTE NPTN ERF BABA SDCJF PAY MSFT GPS MPOYQ HRS FL MLM BLCN MOS SEA CLPS LB CLB ROSEU DBX CF CRDAF KSS CRDAD CI SSI JAG ROSE SNDE DAVA SJM UNT HUM EOG BHI RGRYY MU LGCY SBUX MNK WRD LOW JKS TOL LONE ERF CLB FTK AMAT CRD KEG KEGX SOXX STT FSWB WLL AQST SM LBRT BV LLEX ADIL NBR RGRLF CMG RRC INTU HIMX BJRI EDUC BE MPO ABBV BA ESRX ECR JG NDLS WPXP MTB RRL VMW ALRM LQDA RMBS ECA CANG ICD OPRA IBM WISA CDEV JGPK LYB COG ECA SPDI SBOW PHX TGT NTR BRY HPQ URBN TELL

110
Top Analyst Upgrades and Downgrades: AVEO, Boeing, Canopy Growth, Coty, Kimberly-Clark, Lululemon, Macy’s, Sysco, Teladoc and More

2018-08-16 247wallst - 8
Stocks were indicated to open handily higher after strong Walmart earnings and after reports that China is engaging in new trade talks. Earnings season is now about 85% over, and it has been quite strong with over 70% of the companies exceeding expectations. That said, the stock market volatility in 2018 has created less rewarding trades by buying the dips, which had been so reliable in prior years.
SYY STZ.B GSKY CONN STZ KMB CGC ERJ AVLR TWMJF HIMX AVEO BOE WEED TRI MS BA COTY

 
Himax Technologies, Inc. to Attend Jefferies Semiconductor, Hardware and Communications Infrastructure Summit on August 28th – 29th, 2018

2018-08-16 globenewswire
TAINAN, Taiwan, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced that the Company will attend Jefferies Semiconductor, Hardware and Communications Infrastructure Summit on August 28th – 29th, 2018 at The Ritz-Carlton Chicago.
HIMX

4
Himax Technologies, Inc. (HIMX) CEO Jordan Wu on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Good day, ladies and gentlemen and welcome to the Himax Technologies, Inc. Second Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded.
HIMX QCOM

 
HIMX / Himax Technologies, Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-08-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
HIMX

1
Himax Technologies, Inc. Schedules Second Quarter 2018 Financial Results Conference Call for Thursday, August 9th at 8:00 AM EDT

2018-07-23 globenewswire - 1
TAINAN, Taiwan, July 23, 2018 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq:HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced that it will hold a conference call with investors and analysts on Thursday, August 9th at 8:00 a.m. U.S. Eastern Daylight Time and 8:00 p.m. Taiwan Time to discuss the Company's second quarter 2018 financial results.
HIMX

5
Himax: Dead Cat Bounce

2018-07-17 seekingalpha - 1
The 3D sensing solution project with Qualcomm is the only catalyst for growth for Himax in the foreseeable future.
SYNA HIMX QCOM

HIMX: Himax Technologies Analysis and Research Report

2018-06-24 - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 43289P106